Halozyme Therapeutics Debt 2024

Halozyme Therapeutics Aktienanalyse

What does Halozyme Therapeutics do?

Halozyme Therapeutics Inc is a biotechnology company based in San Diego, California, specializing in the development of therapies for cancer and rare diseases. The company was founded in 1998 and has been listed on the NASDAQ since 2004. The business model of Halozyme is based on the use of the enzyme hyaluronidase, which helps distribute medications more quickly and effectively in the body. By using hyaluronidase, the absorption of medications can be improved, increasing their effectiveness and improving patient treatment. The company operates in three different areas: the first area is the development of its own therapies based on the use of hyaluronidase. Halozyme has several medications in the pipeline, including a therapy for pancreatic cancer and a treatment for muscular dystrophy. The second area is partnering with other pharmaceutical companies to enable faster absorption of their medications through the use of hyaluronidase. Halozyme has entered into over 30 partnerships with companies such as Pfizer, Roche, and Janssen. The third area is the development of diagnostic tools based on the analysis of protein-protein interactions. This technology is intended to accelerate the drug development process and support the selection of the most promising candidates. An example of a product developed by Halozyme in collaboration with a partner company is Herceptin SC (subcutaneous). Herceptin is a medication for the treatment of breast cancer that is typically administered intravenously. However, by adding hyaluronidase, the medication can also be administered subcutaneously, reducing treatment duration and patient burden. Halozyme aims to develop innovative therapies and accelerate the drug development process. By using hyaluronidase and partnering with other companies, the company can contribute to improving the effectiveness of medications and optimizing treatment outcomes for patients. Halozyme Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Halozyme Therapeutics's Debt Structure

Halozyme Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Halozyme Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Halozyme Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Halozyme Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Halozyme Therapeutics stock

What is the debt of Halozyme Therapeutics this year?

Halozyme Therapeutics has a debt level of 1,380.88 USD this year.

What was the debt of Halozyme Therapeutics compared to the previous year?

The debt of Halozyme Therapeutics has increased by 8.57% compared to the previous year increased.

What are the consequences of high debt for investors in Halozyme Therapeutics?

High debt can pose a risk for investors of Halozyme Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Halozyme Therapeutics?

Low debt means that Halozyme Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Halozyme Therapeutics affect the company?

An increase in debt of Halozyme Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Halozyme Therapeutics affect the company?

A reduction in debt of Halozyme Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Halozyme Therapeutics?

Some factors that can influence the debt of Halozyme Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Halozyme Therapeutics so important for investors?

The debts of Halozyme Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Halozyme Therapeutics take to change the debt?

To change the debt, Halozyme Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Halozyme Therapeutics pay?

Over the past 12 months, Halozyme Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Halozyme Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Halozyme Therapeutics?

The current dividend yield of Halozyme Therapeutics is .

When does Halozyme Therapeutics pay dividends?

Halozyme Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Halozyme Therapeutics?

Halozyme Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Halozyme Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Halozyme Therapeutics located?

Halozyme Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Halozyme Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Halozyme Therapeutics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Halozyme Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Halozyme Therapeutics in the year 2023?

In the year 2023, Halozyme Therapeutics distributed 0 USD as dividends.

In which currency does Halozyme Therapeutics pay out the dividend?

The dividends of Halozyme Therapeutics are distributed in USD.